Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$25.86
-2.4%
$24.04
$14.80
$40.47
$1.97B0.86836,586 shs626,383 shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$32.97
-1.1%
$32.14
$26.47
$41.61
$1.89B0.87622,510 shs786,752 shs
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$33.52
-0.3%
$34.05
$27.12
$60.90
$2.01B2.38976,375 shs737,672 shs
Valneva SE stock logo
VALN
Valneva
$6.01
-2.3%
$6.46
$3.62
$8.66
$502.65M1.8142,504 shs12,704 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
-2.42%-3.90%+6.99%-6.98%-27.18%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
-1.08%-7.39%-1.26%+0.76%+11.95%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-0.33%+6.18%+13.55%-16.12%-36.08%
Valneva SE stock logo
VALN
Valneva
-2.28%-2.26%-6.24%-11.62%-28.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.4606 of 5 stars
4.51.00.00.02.90.80.0
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
4.7659 of 5 stars
4.61.00.00.03.53.34.4
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
4.1113 of 5 stars
4.41.00.04.42.20.80.6
Valneva SE stock logo
VALN
Valneva
2.6106 of 5 stars
3.55.00.00.02.50.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
3.00
Buy$58.22125.14% Upside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
3.11
Buy$53.0060.75% Upside
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4050.36% Upside
Valneva SE stock logo
VALN
Valneva
3.00
Buy$15.50157.90% Upside

Current Analyst Ratings Breakdown

Latest VALN, CGON, HRMY, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$61.00
5/19/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.00
5/15/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.00
5/13/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Valneva SE stock logo
VALN
Valneva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
5/6/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
5/2/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$41.00
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$662K2,977.61N/AN/A($1.94) per share-13.33
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$744.85M2.54$2.46 per share13.38$7.97 per share4.14
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$347.68M5.78N/AN/A$7.64 per share4.39
Valneva SE stock logo
VALN
Valneva
$186.06M2.70N/AN/A$2.00 per share3.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$48.61M-$1.51N/AN/AN/A-10,642.98%-18.97%-15.36%8/14/2025 (Estimated)
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$128.85M$2.6215.6310.600.4717.98%23.16%14.24%8/5/2025 (Estimated)
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-59.76%-32.69%-25.25%8/1/2025 (Estimated)
Valneva SE stock logo
VALN
Valneva
-$109.78M-$1.19N/AN/AN/A-4.35%-3.93%-1.42%8/12/2025 (Estimated)

Latest VALN, CGON, HRMY, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million
5/7/2025Q1 2025
Valneva SE stock logo
VALN
Valneva
-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million
5/6/2025Q1 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.59$0.78+$0.19$0.78$184.26 million$184.73 million
5/5/2025Q2 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
3/25/2025Q4 2024
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.37-$0.48-$0.11-$0.48$0.11 million$0.46 million
3/20/2025Q4 2024
Valneva SE stock logo
VALN
Valneva
-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Valneva SE stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
35.32
35.32
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.28
3.24
3.20
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62
Valneva SE stock logo
VALN
Valneva
0.70
2.78
2.25

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A
Valneva SE stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
7.40%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
23.60%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
3.01%
Valneva SE stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.23 millionN/AOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.42 million39.47 millionOptionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.92 million57.86 millionOptionable
Valneva SE stock logo
VALN
Valneva
70083.64 million69.15 millionNot Optionable

Recent News About These Companies

US Advises Older Travelers to Avoid Chikungunya Vaccine

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$25.86 -0.64 (-2.42%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$26.92 +1.06 (+4.11%)
As of 06/13/2025 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$32.97 -0.36 (-1.08%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$33.02 +0.05 (+0.14%)
As of 06/13/2025 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$33.52 -0.11 (-0.33%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$33.51 -0.02 (-0.04%)
As of 06/13/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Valneva stock logo

Valneva NASDAQ:VALN

$6.01 -0.14 (-2.28%)
As of 06/13/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.